Moreover, several recent clinical studies have shown that BRCA1-deficient phenotypes are found with high prevalence not only in breast and ovarian cancers, but also in pancreatic, prostatic, and other types of cancers (Lord and Ashworth, 2016). This evidence concerns the gene BRCA1 and ovarian cancer.